Podcasts about jacc

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Gilbert Tang, Editor-in-Chief of Journal of the American College of Cardiology (JACC): Case Reports, professor in the Department of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, surgical director of the Structural Heart Program at Mount Sinai Health System, and the director of Structural Heart Education at the Mount Sinai Fuster Heart Hospital in New York, NY, USA. They were joined by Drs. Mateo Marin-Cuartas, associate editor of JACC: Case Reports, CTSNet JANS Editor, and cardiac surgeon at Leipzig Heart Center, Germany, and Tsuyoshi Kaneko, Chair of American College of Cardiology (ACC) Cardiac Surgery Member Section and Chief of Cardiac Surgery at Washington University in St. Louis, MO, USA, to discuss JACC: Case Reports. Chapters 00:00 Intro 01:45 Instructional Video Competition 05:30 JANS 1, Lung Cancer Metastasis 09:08 JANS 2, Uncorrected Pectus 11:29 JANS 3, Ambulatory VV Life Support 13:38 JANS 4, EuroSCORE II 14:28 Video 1, TAVR Removal Double Patch 16:09 Video 2, ROK Procedure AF 17:46 Video 3, RATS Lobectomy 19:11 JACC Case Reports 35:28 Upcoming Events 36:03 Career Center They discussed the mission of the journal and the types of submissions it receives. They also covered the types of cases accepted and the various categories within the journal has, such as the "How We Did It" section. Additionally, they talked about the upcoming partnership between JACC: Case Reports and the ACC, as well as past collaborations that JACC has undertaken. Dr. Marin-Cuartas shared insights about his role as an associate editor and highlighted the most interesting case he has encountered in JACC: Case Reports. Furthermore, Dr. Kaneko discussed being the Chair of the ACC Cardiac Surgery Member Section. Joel also highlights recent JANS articles on the evolutionary characterization of lung cancer metastasis, the impact of severe uncorrected pectus excavatum on outcomes after aortic surgery in Marfan syndrome, determining an optimal central cannulation strategy for ambulatory veno-venous extracorporeal life support, and refitting EuroSCORE II for 120-day mortality after coronary artery bypass grafting using nationwide registry data. In addition, Joel explores complex imaging TAVR removal double patch double valve, RATS extended left upper lobectomy with intrapericardial vascular control and bronchoplasty, and ROK procedure for the treatment of atrial fibrillation. Before closing, Joel highlights upcoming events in CT surgery.   JANS Items Mentioned Evolutionary Characterization of Lung Cancer Metastasis Impact of Severe Uncorrected Pectus Excavatum on Outcomes After Aortic Surgery in Marfan Syndrome Determining an Optimal Central Cannulation Strategy for Ambulatory Veno-Venous Extracorporeal Life Support Refitting EuroSCORE II for 120-Day Mortality After Coronary Artery Bypass Grafting Using Nationwide Registry Data CTSNet Content Mentioned Complex Imaging TAVR Removal Double Patch Double Valve RATS Extended Left Upper Lobectomy With Intrapericardial Vascular Control and Bronchoplasty ROK Procedure for the Treatment of Atrial Fibrillation Other Items Mentioned JACC: Case Reports 2026 Instructional Video Competition Winners Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

CardioNerds Dr. Joseph Kassab, Dr. Mariana Garcia-Arango, and Dr. Christopher Mason explore the technological revolution of Coronary CT Angiography (CCTA) with expert faculty Dr. Michael Gallagher. The discussion details how CCTA has evolved into a frontline diagnostic and preventive tool, moving beyond simple anatomy to incorporate physiology via CT-FFR and biology through AI-driven plaque quantification. The episode reviews landmark evidence like the SCOT-HEART and PROMISE trials, the nuances of CAD-RADS 2.0 reporting, and the emerging role of AI in monitoring treatment response and personalizing cardiovascular care. Critically, they also discuss some of the assumptions and limitations of these techniques. Stay tuned for a matching review article to be submitted to US Cardiology Review, the official Journal of CardioNerds. This episode was supported by an independent medical education grant from HeartFlow. All CardioNerds education is planned, produced, and reviewed solely by CardioNerds.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Multimodality Cardiovascular Imaging PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll Pearls Shift in Paradigm: CCTA is no longer just an anatomic test; with some key limitations, it can provide anatomy, physiology (CT-FFR), and plaque biology (AI-CPA) in a single non-invasive scan. The “Power of Zero” vs. Plaque: While a normal CCTA has a >95% negative predictive value, future MIs often arise from non-obstructive plaque that traditional stress tests might miss. CAD-RADS 2.0 Utility: The addition of plaque burden modifiers (P1–P4) is a “game changer,” allowing clinicians to identify high-risk patients who need aggressive lipid-lowering despite having only mild stenosis. CT-FFR as a Virtual Stress Test: CT-FFR uses computational fluid dynamics to simulate blood flow, potentially reducing unnecessary invasive catheterizations by approximately 61% without sacrificing safety. Seeing the Invisible: AI-based quantitative plaque analysis (QCPA) can identify “subvisual” plaque and low-attenuation (lipid-rich) components that are the primary drivers of acute coronary syndromes. Show Notes How has the role of CCTA changed compared to traditional functional testing? Historically, stress testing answered “is there ischemia today?”, which often reflects late-stage disease. CCTA identifies disease across the entire spectrum, asking “is there atherosclerosis and how much plaque is present?”. Landmark evidence: SCOT-HEART showed a 41% relative risk reduction in MI at 5 years attributed to intensified preventive therapies, and PROMISE showed CCTA was better at selecting patients who truly needed invasive angiography. Diagnostic CCTA imaging depends on the protocol, contrast timing, heart rate, heart rhythm, breathholding, scanner quality, and several patient factors (obesity, prior stents, heavy calcification, complex bypass anatomy, and motion artifact all may limit imaging). “CCTA is exceptional for the right patient, with the right scanner, and the right team.” What are the key modifiers introduced in CAD-RADS 2.0, and why do they matter? CAD-RADS 2.0 moved beyond stenosis severity to include plaque burden (P0 to P4), high-risk plaque (HRP) features, and the presence of ischemia based on CT-FFR. It serves as a clinical decision support tool: a patient with mild (25-49%) stenosis but “extensive” (P4) plaque burden is considered high risk and warrants aggressive risk factor modification. How is CT-FFR calculated, and when is it most useful in clinical practice? CT-FFR uses resting CCTA data and computational fluid dynamics to create a 3D model of coronary flow during simulated maximal hyperemia. It is often used for intermediate lesions (40–90% stenosis) to predict if they are  ischemia-producing, guiding the decision whether to proceed with invasive angiography.  The assumptions necessary for this computational modeling may not apply well to patients with microvascular dysfunction, significant myocardial scar or prior infarction, or ventricular hypertrophy. Still, data indicate that CT-FFR performs similarly to PET in predicting hemodynamically significant lesions.  CT-FFR performs well at the extremes (either clearly normal or clearly abnormal). Accuracy dips, however, in the intermediate range (~0.75-0.80), where decision-making is most critical. In this grey zone, additional factors can help guide the approach, including the amount of myocardium supplied, translesional gradient, and plaque features.   CT-FFR has not been validated in distal segments, stented segments, heavily calcified coronary arteries, or in patients with severe aortic stenosis. Caution with CT-FFR should be utilized in very calcified coronary segments.  What is AI-based quantitative plaque analysis (QCPA), and what metrics are ready for clinical use? This is potentially a paradigm shift, moving away from stenosis-centric thinking to a more disease burden and plaque biology focus. QCPA uses deep learning algorithms to automatically segment the vessel wall and quantify plaque volume in mm³. Ready for “prime time” metrics include: Total Plaque Volume (TPV), non-calcified plaque volume, and Low-Attenuation Plaque (LAP) burden. Can serial CCTA be used to monitor the effectiveness of medical therapies like statins? While not yet a routine guideline-driven practice, trials like PARADIGM and EVAPORATE show that therapies can stabilize plaque; notably, CCTA is better for monitoring than CAC scores, which can be misleading as statins often increase plaque calcification as part of the stabilization process. There are no randomized trials that serial CCTAs improve outcomes. Cost and radiation exposure will be notable limitations. Serial scan timing, scan acquisition and interpretation standardization would be key. Dr. Gallagher notes that we are moving toward a world in which plaque burden may become a “treatment biomarker,” similar to tumor burden in oncology.  References 1. Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies: JACC State-of-the-Art Review. Abdelrahman KM, Chen MY, Dey AK, et al. Journal of the American College of Cardiology. 2020;76(10):1226-1243. doi:10.1016/j.jacc.2020.06.076. 2. Non-Invasive Imaging in Coronary Syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in Collaboration With the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Edvardsen T, Asch FM, Davidson B, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2022;35(4):329-354. doi:10.1016/j.echo.2021.12.012. 3. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053. 4. Contemporary, Non-Invasive Imaging Diagnosis of Chronic Coronary Artery Disease. van der Bijl P, Gulati M, Saraste A, et al. Lancet (London, England). 2025;406(10519):2577-2587. doi:10.1016/S0140-6736(25)01586-7. 5. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394. 6. Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography: The ACCURATE-CT Study. Li C, Hu Y, Jiang J, et al. JACC. Cardiovascular Interventions. 2024;17(17):1980-1992. doi:10.1016/j.jcin.2024.06.027. 7. Clinical Outcomes Based on Coronary Computed Tomography-Derived Fractional Flow Reserve and Plaque Characterization. Sato Y, Motoyama S, Miyajima K, et al. JACC. Cardiovascular Imaging. 2024;17(3):284-297. doi:10.1016/j.jcmg.2023.07.013. 8. Clinical Use of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve: Expert Consensus by an International Working Group. Tang CX, Leipsic JA, Nørgaard BL, et al. European Radiology. 2026;:10.1007/s00330-025-12313-6. doi:10.1007/s00330-025-12313-6. 9. Diagnostic accuracy of computed tomography–derived fractional flow reserve: a systematic review. Cook CM, Petraco R, Shun-Shin MJ, et al. JAMA Cardiol. 2017;2(7):803-810. Doi:10.1001/jamacardio.2017.1314 10. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). Nørgaard BL, Leipsic J, Gaur S, et al. J Am Coll Cardiol. 2014;63(12):1145-1155. Doi:10.1016/j.jacc.2013.11.043 11. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. Driessen RS, Danad I, Stuijfzand WJ, et al. J Am Coll Cardiol. 2019;73(2):161-173. Doi:10.1016/j.jacc.2018.10.056. 12. 1-year outcomes of FFRCT-guided care in patients with suspected coronary disease: the PLATFORM study. Douglas PS, De Bruyne B, Pontone G, et al. J Am Coll Cardiol. 2016;68(5):435-445. Doi:10.1016/j.jacc.2016.05.057. 13. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized clinical trial. Douglas PS, Nanna MG, Kelsey MD, et al; PRECISE Investigators. JAMA Cardiol. 2023;8(10):904-914. Doi:10.1001/jamacardio.2023.2595. 14. Diagnostic and clinical value of FFRCT in stable chest pain patients with extensive coronary calcification: the FACC study. Mickley H, Veien KT, Gerke O, et al. JACC Cardiovasc Imaging. 2022;15(6):1046-1058. doi:10.1016/j.jcmg.2021.12.010. 15. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Williams MC, Kwiecinski J, Doris M, et al. Circulation. 2020;141(18):1452-1462. doi:10.1161/CIRCULATIONAHA.119.044720. 16. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. Nurmohamed NS, Bom MJ, Jukema RA, et al. JACC. Cardiovascular Imaging. 2024;17(3):269-280. doi:10.1016/j.jcmg.2023.05.020. 17. Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry. Dundas J, Leipsic J, Fairbairn T, et al. Circulation. Cardiovascular Imaging. 2024;17(3):e016143. doi:10.1161/CIRCIMAGING.123.016143. 18. Prognostic Value of AI-Based Quantitative Coronary CTA vs Human Reader-Based Visual Assessment: Results From the CONFIRM2 Registry. van Rosendael A, Nakanishi R, Bax JJ, et al. JACC. Cardiovascular Imaging. 2026;19(3):345-359. doi:10.1016/j.jcmg.2025.09.021.13. Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk: JACC Review Topic of the Week. Tan N, Dey D, Marwick TH, Nerlekar N. Journal of the American College of Cardiology. 2023;81(9):913-923. doi:10.1016/j.jacc.2022.12.021. 19. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: Final Results of the EVAPORATE Trial. Budoff MJ, Bhatt DL, Kinninger A, et al. European Heart Journal. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652. 20. Coronary CT Angiography Evaluation With Artificial Intelligence for Individualized Medical Treatment of Atherosclerosis: A Consensus Statement From the QCI Study Group. Schulze K, Stantien AM, Williams MC, et al. Nature Reviews. Cardiology. 2026;23(2):100-115. doi:10.1038/s41569-025-01191-6.

Send us Fan MailDeep-dive into a 2026 cardiology review paper claiming seed oils reduce inflammation, exposing misrepresentations of cited clinical trials, and detailing how oxidized Ω-6 fats trigger inflammation.Companion article: Click HERETOPICS DISCUSSED:Seed Oil Profiles: Typical seed oils like sunflower are high in linoleic acid (omega-6 PUFA), while canola is higher in monounsaturated fats and resembles olive oil.Review Paper Critique: The 2026 JACC review falsely claims sunflower oil reduce inflammation like olive oil, citing an RCT that showed benefits only for canola and olive.RCT Analysis: In Iranian women with metabolic issues, switching to canola or olive oil lowered CRP by increasing MUFA and decreasing PUFA intake; sunflower oil produced no change.CRP Biology: CRP responds to oxidized lipids and cellular damage patterns, rising with exercise or infection and marking oxidized Ω-6 metabolites in modern diets.Oxidized Lipids: Ω-6 fats in LDL and cardiolipin oxidize easily, generating 4-HNE, MDA, and other signals that trigger immune clearance, similar to bacterial threats.Sterile Inflammation: High dietary linoleic acid causes chronic immune activation without pathogens, potentially contributing to metabolic and cardiovascular issues.PRACTICAL TAKEAWAYS:Prioritize monounsaturated fats from olive or avocado oil over high-linoleic seed oils like standard sunflower or soybean for lower oxidative stress potential.Check labels for high-oleic versions of sunflower oil, which shift the profile toward monounsaturated fats.Evaluate nutrition claims by examining original studies and fatty acid compositions rather than accepting review summaries at face value.Support the showHealth Products by M&M Partners:AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models.OmegaQuant: At-home blood testing to see fatty acid profiles, including omega-3 fatty acids. Use link to see options and support M&M.SiPhox Health: Comprehensive, cost-effective bloodwork from the comfort of home. Use code TRIKOMES for 20% off.KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime)SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off.For all the ways you can support my efforts

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Long-Term Outcomes of Targeted Volume Overload Management in Patients With Severe Aortic Stenosis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Generalizability of Landmark Temporary MCS Device Trials: Insights From the CSWG Registry.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Early Diagnosis of ATTR-CM by Age- and Carpal Tunnel Biopsy-Guided Screening.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Comparison of Microcirculation in Chronic Heart Failure, Cardiogenic Shock, LVAD, and Heart Transplantation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Characteristics, Management, and Outcomes of Diabetes Subtypes in Patients With Cardiogenic Shock: A Nationwide Analysis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in Cardiac Involvement in Adults With Myotonic Dystrophy Type 1: A Multicenter Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Differential Association Between Surrounding Greenness and Mortality in Individuals With Coronary Heart Disease.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Accelerometer-Measured Sedentary Behavior, Future Disease, and Cardiovascular-Kidney-Metabolic Health.

Dr. Mohamad Alkhouli speaks with Dr. Wayne Batchelor about what leadership truly means for mid‑career interventional cardiologists and whether pursuing an MBA adds value. Dr. Batchelor highlights trust, communication, and business fluency as essential skills for physician leaders navigating increasingly complex healthcare systems.

Dr. Mohamad Alkhouli and Dr. Deepak Bhatt discuss leadership development in interventional cardiology and the value of pursuing an executive MBA mid‑career. Dr. Bhatt shares insights on how business training—from finance to leadership and strategy—can help physicians navigate increasingly complex healthcare systems and become more effective stewards of patient care and resources.

In this conversation, Dr. Mohamad Alkhouli speaks with Dr. Abbott about her leadership journey in interventional cardiology, focusing on how curiosity, mentorship, and skill development organically lead to meaningful leadership roles. Dr. Abbott shares practical insights on motivating teams, navigating complex healthcare systems, and whether formal business training such as an MBA is necessary for physician leaders.

Dr. Mohamad Alkhouli and Dr. Kirk Garratt discuss leadership in interventional cardiology, highlighting the importance of empathy, communication, and advocacy alongside clinical expertise. Dr. Garratt encourages physicians to intentionally develop leadership skills—through training or experience—as healthcare systems become more complex.

Commentary by Dr. Satoshi Shizuta.

Commentary by Dr. Leandra Serio.

Commentary by Dr. Deep Chandh Raja.

Commentary by Dr. Katsuhiko Imai.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Associations of Socioeconomic Status With Cardiorenal Metabolic Multimorbidity: Evidence From the UK Biobank Cohort.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Dietary Sodium Intake and Risk of Incident Heart Failure in the Southern Community Cohort Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Remote Management of Patients With Heart Failure in Medically Underserved Areas.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Development of a Predictive Tool in Patients With High Pretest Probability for Transthyretin Amyloid Cardiomyopathy.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Valvular Heart Diseases in Swedish Males and Females: A National Cohort Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Cardiovascular-Kidney-Metabolic Syndrome and Life Expectancy in U.S. Adults.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on 10-Year Excess Mortality After First-Time Non–ST-Segment Elevation Myocardial Infarction: The Western Denmark Heart Registry.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Coronary Sinus Reduction for REDUCER-I Patients With Refractory Angina and Angiographically Nonobstructive Coronary Artery Disease.

Commentary by Dr. Elvin Kedhi.

Dr. Michel G. Khouri reviews a landmark study examining patients with AL amyloidosis who achieved a complete cardiac biomarker response, highlighting profound improvements in cardiac structure, function, and long-term survival that rival the general population. The discussion underscores the transformative impact of early diagnosis and modern plasma cell–directed therapies, while reminding clinicians that ongoing multidisciplinary cardiac care remains essential even after sustained cardiac remission.

Dr. Qun Shao discusses two multicenter studies evaluating cardiovascular adverse events associated with bispecific T‑cell engager therapies. Drawing on data from over 700 patients, the episode highlights the incidence, predictors, and clinical impact of cardiovascular complications, emphasizing the importance of baseline risk assessment, targeted monitoring, and multidisciplinary management as use of these therapies continues to expand.

Research fellow, Adrian Chen, discusses a multicenter study evaluating myocardial PD‑L1 expression as a prognostic biomarker in immune checkpoint inhibitor–associated myocarditis. The conversation highlights how elevated myocardial PD‑L1 identifies patients at markedly higher risk for early adverse cardiac events and explores its potential role in improving risk stratification and guiding earlier, more aggressive therapy in this high‑risk population.

Dr. Ky's full issue summary.

In this special Season 2 wrap-up of JACC This Week, Dr. Harlan Krumholz and Dr. Carolyn Lam reflect on the pilot season, the energy of ACC.26, and what they've learned from listeners along the way. From quick journal highlights to deeper editorial conversations, they discuss the different ways audiences want to engage with JACC content—and why the next iteration of the podcast will continue evolving with listener feedback in mind. Thank you for listening, sharing your thoughts, and being part of the journey.